Anti-PCSK9 Antibody and Application Thereof



Zeng Jun, Claude, Eric Berk, Jonathan P, Mavericks, Zhang Min, Bolan, Ned Sai Kaen, Liu Xiaolin, Yu Dechao


  1. Cinda Biopharmaceutical (Suzhou) Co., Ltd.


The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and the fragment in treatment and diagnosis..

CovalX Technology Used

Epitope Mapping



Complex Tracker


An antibody/antigen complex was prepared using the following concentrations:

People of PCSK9 (PCSK9-WT)





8 μM

5 μL

1 μM

10 μL

0.5 μM/4 μM

1 μL of the antibody/antigen complex was mixed with 1 μL of sinapic acid matrix (10 mg/ml in acetonitrile/water (1:1, v/v) with 0.1% TFA) before 1 μL of the final mixture was plated on a MALDI target and allowed to crystallize at room temperature before being analyzed. The remaining 9 μL of the CovalX K200 Stabilization Kit were mixed with 1 μL of the antibody/antigen complex and incubated at room temperature for 180 minutes to allow for the cross-linking reaction to proceed. In order to characterize the  complex, a mass spectrometer that had been modified with a CovalX HM4 detection system was used. The data was analyzed using the CovalX Complex Tracker software. From this analysis, researchers determined that PCSK9-WT is reduced and that the PCSK9-WT anti-PCSK9 antibody can bind.

In another experiment, the same antibody/antigen complex was created and 1mg of deuterated DSS (d12) from CovalX was used as part of the cross-linking reaction. 1 mg of DSS (d0) and 1 mg of the deuterated DSS (d12) were mixed with 1 ml of DMF. 10 μL of the d0 agent was mixed with the antibody/antigen complex as well as 1 μL of the d12 agent before being incubated at room temperature for 180 minutes to allow for the cross-linking reaction to proceed.

Patent Number

WO2018/113781 A1

Contact our Scientific Team to Start the Conversation

Request A Call
Categories : Patents, Epitope Mapping